← board
NAMSW
distress 0/10 · well-funded / low risk$19.38+4%today-35% from 52w high
Lead: ASCVD and/or HeFH
Revenue
pre-revenue
Liquidity
$707M
Runway
5.0 yrs
Shares 1y
+4%
Price & events
-15.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.5%
1D
-5.7%
1W
+3.7%
1M
-12.7%
3M
-15.3%
6M
+72.0%
1Y
+113.0%
2Y
+1669.9%
5Y
+660.0%
All
Overview
- Market Cap
- $2.27B
- Volume
- 200
- 52 Week Range
- $9.55 – $29.99
- Total Shares
- 116.90M
- Float Shares
- 80.70M
- RVOL
- 0.28x
- Beta
- 0.08
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2025regulatory submissionFiled (NDA/BLA)obicetrapib · Meeting with regulatory authorities to discuss filingsSEC 8-K
- 2024-12-10withdrawalTerminated ATM prospectus for sale of up to $150 million of ordinary shares.SEC 8-K
- November 18, 2024, 2:14 p.m. CSTconferencedata presentationsecondaryPhase 3obicetrapib · Additional efficacy and safety data from BROOKLYN trial presented at AHA 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — ASCVD and/or HeFH
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.